Unanswered questions regarding the management of sunitinib-induced hypothyroidism.
Garfield
David
D
Department of Medicine, University of Colorado Health Sciences Center, Denver, CO 80209, USA. david.garfield@earthlink.net
Hercbergs
Aleck
A
Davis
Paul
P
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D006801:Humans; D007037:Hypothyroidism / Q000139:chemically induced* / Q000188:drug therapy*; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects*; D009369:Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D011758:Pyrroles / Q000008:administration & dosage / Q000009:adverse effects*; D000077210:Sunitinib; D013963:Thyroid Hormones / Q000008:administration & dosage / Q000009:adverse effects*
D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D013963:Thyroid Hormones; D000077210:Sunitinib